Sign inJoin waitlistJoin the waitlist

NB

Nicole Baca

Physician · Cedars-Sinai Medical Center

Credentials: · ·

History

Cedars-Sinai Medical Center
2024–Present

Pediatric Hematology/Oncology
University of California
2015–2018
Pediatrics
University of Nevada School of Medicine Pediatrics
2012–2015
Univ of Nevada Sch of Med
2007–2011

Research

Altered type 1 interferon responses in alloimmunized and nonalloimmunized patients with sickle cell disease
eJHaem · 2021 · 13 citations
Lupus anticoagulant hypoprothrombinemia syndrome associated with severe thrombocytopenia in a child
Case report · Pediatric Blood & Cancer · 2017 · 10 citations
A Multicomponent Telehealth Intervention to Improve Oncofertility Care Delivery Among Young Cancer Patients: A Pilot Study
Journal of Adolescent and Young Adult Oncology · 2023 · 7 citations

FM
Fataneh Majlessipour
8 papers
SA
Saro Armenian
3 papers
CL
Carol Lin
2 papers
David Freyer
2 papers
Dennis Kuo
2 papers
Lilibeth Torno
2 papers
AF
Aimee Foord
1 paper
AD
Anna Dornisch
1 paper · 1 as a resident
AM
Arash Mahajerin
1 paper
Behrooz Hakimian
1 paper
Bonnie Balzer
1 paper
CH
Chelsea Halprin
1 paper · 1 as a resident

Clinical trials

Identification of Pre-Malignant Lesions In Pediatric Patients With Neurofibromatosis Type 1 Using Novel Magnetic Resonance Imaging Techniques Paired With Artificial Intelligence
Principal investigator · Recruiting
Nicole Baca
2022–2029
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2023–2031
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2020–2028
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Site PI · Recruiting · Phase 3
Children's Oncology Group
2019–2032